Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

CAMBRIDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. announced top-line data today from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer liquid, an investigational, non-antibiotic, polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer liquid is fully enrolled and results are expected later this year.

In this first Phase 3 study known as the Polymer Alternative for CDAD Treatment (PACT) study, tolevamer liquid did not meet its primary endpoint of non-inferiority to the standard prescribed oral dose of the antibiotic vancomycin, as measured by the percent of patients with resolution of CDAD. This result contrasts with the findings from Genzyme's earlier Phase 2 study of a solid oral dosage formulation of tolevamer that met its primary endpoint of non-inferiority compared to vancomycin.

Consistent with recent published studies, high rates of CDAD recurrences were observed in patients treated with either vancomycin or metronidazole. High CDAD recurrence rates were not observed in patients treated with tolevamer liquid. Tolevamer liquid was generally well tolerated with no unanticipated safety concerns. Data from this first Phase 3 study is expected to be presented at a future medical conference.

"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," stated Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "The results of our second Phase 3 study will be available later this year and will help us determine what contribution tolevamer might be able to make in addressing this serious unmet medical need."

C. difficile has become one of the most significant infection control concerns in healthcare today. Physicians worldwide are confronting a worsening epidemic, with an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced that it ... 30, 2015 results on Thursday, July 30, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has ... Imaging and by Application - Forecast to 2020" report to ... to reach $13.1 Billion in 2020 from an estimated $7.1 Billion ... market is dominated by North America , followed ... and Rest of the World (RoW). The cancer diagnostics market in ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... , , ... presented today from the SPIRIT III pivotal U.S. clinical ... XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase ... (TAXUS). At three years, XIENCE V demonstrated a 43 percent ...
... , REYKJAVIK, Iceland, September 20 ... of DNA-Based Testing to Identify Men at,Substantially Increased Risk, and ... deCODE genetics (Nasdaq: DCGN ) today announced ... Spain, the Netherlands and,the United States have today published the ...
Cached Medicine Technology:Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 2Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 3Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 4Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 5Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial 6deCODE Discovers Four New Risk Factors for Prostate Cancer 2deCODE Discovers Four New Risk Factors for Prostate Cancer 3deCODE Discovers Four New Risk Factors for Prostate Cancer 4
(Date:7/3/2015)... ... 2015 , ... Jennifer Renee Hanes, DO is the new Medical Director of ... of independent freestanding emergency rooms in the United States. , “We are excited to ... said Executive Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. ...
(Date:7/3/2015)... , ... July 03, 2015 , ... " Selfie on ... which features the latest and coolest technology products available to consumers. Amanda Forstrom, a ... how these selfie sticks are great for documenting memories. , Almost every smartphone has ...
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness and the Red ... of the Red Deer community with free fitness training and indoor fitness boot camp ... events and entertainment raised thousands of charity dollars and ended with a $10,000 donation ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Mississippi. The premium frozen yogurt chain was listed as #22 on the Inc. 500 ... Avenue, New Albany, MS 38652, will have a grand opening event on July 4, ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in the Lone Star State. The premium frozen yogurt chain was listed as ... store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... 30 Paul Helmke, President,of the Brady Campaign ... the announcement yesterday by Attorney General Michael B.,Mukasey ... disqualifying mental,health records submitted to the Brady background ... emphasizes the critical need to,get all relevant records ...
... Partnership Yields Record Long Term Care Insurance Sales, ... (Amex:,NHC; NHC.PR.A), Tennessee,s most prominent marketer of long-term ... sales growth for 2007.,Long Term Care Associates, Inc., ... together, both companies have expanded their year-over-year,sales growth ...
... Testing 1 Million Angelenos Within Three Years, LOS ... Mayor Antonio Villaraigosa today as he launched the City ... 1 million Angelenos,within the next three years. The Mayor ... the Ramona Gardens community to underscore the,importance of "early ...
... disease and significantly cuts death rates, reveal the fifth year ... The figures, published ahead of print in the journal Gut, ... the Midlands. , This was the only area in England ... those aged 50 to 69, using postal tests that pick ...
... High blood-fat levels not always linked to higher stroke risk, ... link between high cholesterol and heart disease is clear to ... finds the connection between cholesterol levels and stroke is a ... 70s and 80s, the review found that high cholesterol actually ...
... Oriental,Bioengineering Inc. (NYSE: AOB ), a leading manufacturer ... that,the company will present at the ICR XChange Asia ... Conference Center in New York,City., Management,s presentation will ... located at Three Times Square in New York City. ...
Cached Medicine News:Health News:DOJ Report on Mental Health Records Shows Critical Need to Strengthen Brady System 2Health News:National HealthCare Recognized for Outstanding Sales Leadership by Long Term Care Associates, Inc. 2Health News:Mayor Antonio Villaraigosa Partners With AltaMed Health Services to Launch City of Los Angeles HIV Testing Initiative 2Health News:Bowel cancer screening halves emergency admissions and cuts deaths 2Health News:Cholesterol-Stroke Relationship Puzzles Researchers 2Health News:Cholesterol-Stroke Relationship Puzzles Researchers 3Health News:American Oriental Bioengineering to Present at the ICR XChange Asia Institutional Investor Conference 2
... SurgMaster OES Pro Resectoscope is based on ... resectoscope and enables the surgeon to perform ... exchanging the working element, HF cable and ... upgraded for resection in saline, supporting both, ...
... The world's first and only Laser ... comfortable and precisely. This innovative combination ... Intraocular Surgery. A Laser phacoemulsification device ... fragmentational energy and transmits it directly, ...
... PRECISION represents a major advance in ... focused to cover pain. This is ... you need it, anywhere along the ... independent current sources for each of ...
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Medicine Products: